比较托珠单抗生物类似药BAT1806/BIIB800与参照托珠单抗在甲氨蝶呤应答不佳的中重度类风湿关节炎患者中的疗效:一项3期、随机、多中心、双盲、阳性对照临床试验
这项3期、多中心、随机、双盲、阳性对照等效性研究纳入621例对甲氨蝶呤应答不佳的活动性类风湿关节炎患者,比较BAT1806/BIIB800与参照托珠单抗。第12周ACR20应答率参照药组64.8% vs 生物类似药组69.0%(治疗差异4.1%,95%CI -3.6至11.9),第24周分别为67.9% vs 69.9%(治疗差异1.9%,90%CI -4.0至7.9;95%CI -5.2至9.1),所有置信区间均在预设等效界值内。两组药代动力学和免疫原性特征相当,不良事件发生率相似。
要点
- BAT1806/BIIB800与参照托珠单抗在ACR20应答率上达到等效,第12周和第24周置信区间均在预设等效界值内。
- 两组药代动力学和免疫原性特征相当,不良事件发生率相似。
- 参照托珠单抗组5例(1例)和BAT1806/BIIB800组(4例)发生致死性事件。
核心结论
- BAT1806/BIIB800与参照托珠单抗相比,显示出等效的疗效以及相当的安全性、免疫原性和药代动力学特征。
研究设计与样本
- 3期、多中心、随机、双盲、阳性对照等效性研究,包含24周初始治疗期(本文报告结果)和24周后续治疗期。
- 在五个国家(中国、乌克兰、波兰、格鲁吉亚和保加利亚)的54个中心招募对甲氨蝶呤应答不佳的活动性类风湿关节炎患者。
- 患者按1:1:2随机分配至参照托珠单抗至第48周组、参照托珠单抗至第24周后换用BAT1806/BIIB800至第48周组(两个参照托珠单抗组在本次分析中合并为一组)、或BAT1806/BIIB800至第48周组,每4周静脉输注一次,起始剂量8 mg/kg。
- 共随机分配621例参与者:参照托珠单抗组309例,BAT1806/BIIB800组312例。
- 主要终点为第12周(针对欧洲药品管理局[EMA])或第24周(针对美国食品药品监督管理局[FDA]和中国国家药品监督管理局[NMPA])达到美国风湿病学会20%改善标准(ACR20)的参与者比例,采用预设等效界值(95%CI -14.5至+14.5 [EMA]、90%CI -12.0至+15.0 [FDA]、95%CI -13.6至+13.6 [NMPA])。
主要发现
- 第12周估计ACR20应答率:参照托珠单抗组64.8% vs BAT1806/BIIB800组69.0%,治疗差异4.1%(95%CI -3.6至11.9)。
- 第24周估计ACR20应答率:参照托珠单抗组67.9% vs BAT1806/BIIB800组69.9%,治疗差异1.9%(90%CI -4.0至7.9;95%CI -5.2至9.1)。
- 所有置信区间均包含在预设等效界值内。
- 参照托珠单抗组和BAT1806/BIIB800组观察到相当的药代动力学和免疫原性特征。
- 不良事件:参照托珠单抗组201例(65%) vs BAT1806/BIIB800组206例(66%)报告不良事件;治疗中出现的不良事件:参照托珠单抗组196例(63%) vs BAT1806/BIIB800组201例(64%);致死性事件:参照托珠单抗组1例 vs BAT1806/BIIB800组4例。
关键数值与推荐
- 主要终点ACR20应答率等效界值:EMA要求95%CI在-14.5至+14.5之间,FDA要求90%CI在-12.0至+15.0之间,NMPA要求95%CI在-13.6至+13.6之间。
- 第12周ACR20治疗差异4.1%(95%CI -3.6至11.9),第24周治疗差异1.9%(90%CI -4.0至7.9;95%CI -5.2至9.1),均落在预设等效界值内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biosimilars provide an opportunity to address unmet medical need by expanding access to biological treatments. This study aimed to show equivalent efficacy, and comparable safety, immunogenicity, and pharmacokinetic profiles of a proposed tocilizumab biosimilar BAT1806/BIIB800, to reference tocilizumab, in participants with rheumatoid arthritis with an inadequate response to methotrexate. METHODS: This phase 3, multicentre, randomised, double-blind, active-controlled, equivalence study comprised a 24-week initial treatment period (results reported here) and a 24-week secondary treatment period. Participants were recruited at 54 centres across five countries (China, Ukraine, Poland, Georgia, and Bulgaria). Patients with active rheumatoid arthritis with an inadequate response to methotrexate were randomly assigned (1:1:2) to receive reference tocilizumab up to week 48, or reference tocilizumab up to week 24 followed by BAT1806/BIIB800 up to week 48 (the two reference tocilizumab groups were analysed as a single group in this analysis), or BAT1806/BIIB800 up to week 48 (the BAT1806/BIIB800 group), administered by intravenous infusion once every 4 weeks at a starting dose of 8 mg/kg. The primary endpoint was the proportion of participants who had a 20% improvement in American College of Rheumatology criteria (ACR20) at week 12 (for the European Medicines Agency [EMA]) or week 24 (for the US Food and Drug Administration [FDA] and China National Medical Products Administration [NMPA]) using prespecified equivalence margins (95% CI -14·5 to +14·5 [EMA], 90% CI -12·0 to +15·0 [FDA], and 95% CI -13·6 to +13·6 [NMPA]). The International Council for Harmonisation E9(R1) estimand framework, with strategies for addressing intercurrent events, was implemented for the efficacy evaluations with expected differences as per the predefined equivalence margins. This trial is registered at ClinicalTrials.gov (NCT03830203) and EudraCT (2018-002202-31), and is closed to new participants. FINDINGS: Between Dec 19, 2018, and Jan 5, 2021, we randomly assigned 621 participants: 309 to the reference tocilizumab group and 312 to the BAT1806/BIIB800 group. The mean age was 50·5 years (SD 12·0), 534 (86%) were women, 87 (14%) were men, and 368 (59%) were White. For the primary estimands, estimated ACR20 response rates were 64·8% in the reference tocilizumab group and 69·0% in the BAT1806/BIIB800 group (treatment difference 4·1% [95% CI -3·6 to 11·9]) at week 12, and 67·9% in the reference tocilizumab group and 69·9% in the BAT1806/BIIB800 group (treatment difference 1·9% [90% CI -4·0 to 7·9; 95% CI -5·2 to 9·1]) at week 24. All confidence intervals were contained within the predefined equivalence margins. Comparable pharmacokinetic and immunogenicity profiles were observed for the reference tocilizumab and BAT1806/BIIB800 groups. Adverse events were reported by 201 (65%) participants in the reference tocilizumab group and 206 (66%) in the BAT1806/BIIB800 group; 196 (63%) participants in the reference tocilizumab group and 201 (64%) participants in the BAT1806/BIIB800 group reported a treatment-emergent adverse event. Five participants had a fatal event (reference tocilizumab n=1; BAT1806/BIIB800 n=4). INTERPRETATION: BAT1806/BIIB800 showed equivalent efficacy, and comparable safety, immunogenicity, and pharmacokinetic profiles as reference tocilizumab. FUNDING: Bio-Thera Solutions and Biogen.
引用
- Leng X, Leszczyński P, Jeka S, et al. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. Lancet Rheumatol. 2024. PMID: 38258678. doi:10.1016/S2665-9913(23)00237-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。